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Objectives: Antibiotic allergy represents a major clinical challenge in the manage-
ment of patients with cystic ﬁbrosis. Our aim was to examine the prevalence of
allergic reactions within a large adult CF centre and evaluate the cost implications
with regard to desensitisation, additional hospital stay and the use of more expensive
alternative antibiotics.
Methods: The medical records of 375 patients were reviewed to assess the
frequency of allergic reactions and patient characteristics. A cohort of chronic
Pseudomonas patients regarded as ‘allergic’ (two or more beta-lactam reactions)
were then identiﬁed and compared to a matched chronic Pseudomonas cohort
of ‘non-allergic’ patients (tolerant to beta-lactams). Every treatment course was
assessed in detail between 01/01/2013 and 01/01/2014.
Results: 302 beta lactam reactions were identiﬁed in 375 patients. Ceftazidime and
Pipercillin had the highest rates of reaction with 106 (28%) and 101 (27%) patients
having had a previous reaction. Over a one year period 52 desensitisations were
performed with a success rate of 94%. Ceftazidime accounted for 36.5% of the
total number of desensitisations. The average drug cost per treatment course in the
allergic group was 44% higher than that of the matched non-allergic group (£924.10
vs £517.36, p 0.001). When factoring in the cost of desensitisation, home IVs and
hospital stay, the average total cost for a course of treatment for an allergic patient
is £4263.85 compared with £3441.62 to that of a non-allergic patient (p 0.05).
Conclusion: In conclusion, beta-lactam reactions are common and have major cost
implications.
